Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

We aimed to identify diagnosis-specific/transdiagnostic/transoutcome multivariable
candidate predictors (MCPs) of key outcomes in mental disorders. We conducted an …

The long‐term benefit‐to‐risk ratio of sustained antipsychotic treatment for schizophrenia
has recently been questioned. In this paper, we critically examine the literature on the long …

According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …

The search for clinical outcome predictors for schizophrenia is as old as the field of
psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors …

Since currently available antipsychotic medications predominantly treat hallucinations,
delusions, disorganized thoughts and behavior, and related agitation/aggression, attention …

Objective: This study compared relapse prevention and acceptability of long-acting
injectable (LAI) antipsychotics in the maintenance treatment of adults with nonaffective …

Although treatment-resistant schizophrenia (TRS) was described 50 years ago 1 and has a
gold standard treatment with clozapine based on well-defined criteria, 2 there is still a matter …

Importance Negative symptoms represent a substantial burden in schizophrenia. Although
preliminary studies have suggested that transcranial direct current stimulation (tDCS) is …

Early response to antipsychotic medications is one of the most important determinants of
later symptomatic and functional outcomes in psychosis. Glutathione and glutamate have …